Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.
Company profile
Ticker
REGN
Exchange
Website
CEO
Leonard Schleifer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
REGENERON PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Checkmate Pharmaceuticals, Inc. • Eastside Campus Holdings LLC • Loop Road Holdings LLC • Old Saw Mill Holdings LLC • OSMR Holdings • Regeneron Assurance, Inc. • Regeneron Atlantic Holdings • Regeneron Belgium BV • Regeneron Canada Company • Regeneron Genetics Center LLC ...
IRS number
133444607
REGN stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
29 Mar 23
10-K
2022 FY
Annual report
6 Feb 23
8-K
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
3 Feb 23
8-K
J.P. Morgan Healthcare Conference 2023 Strategy & Business Update 2 Leonard S. Schleifer, MD, PhD Co - Founder, President & Chief Executive Officer
9 Jan 23
8-K
Entry into a Material Definitive Agreement
20 Dec 22
UPLOAD
Letter from SEC
7 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Regeneron Reports Third Quarter 2022 Financial and Operating Results
3 Nov 22
CORRESP
Correspondence with SEC
7 Oct 22
8-K
Departure of Directors or Certain Officers
3 Oct 22
Transcripts
REGN
Earnings call transcript
2022 Q4
3 Feb 23
REGN
Earnings call transcript
2022 Q3
3 Nov 22
REGN
Earnings call transcript
2022 Q2
3 Aug 22
REGN
Earnings call transcript
2022 Q1
4 May 22
REGN
Earnings call transcript
2021 Q4
4 Feb 22
REGN
Earnings call transcript
2021 Q3
4 Nov 21
REGN
Earnings call transcript
2021 Q2
5 Aug 21
REGN
Earnings call transcript
2021 Q1
6 May 21
REGN
Earnings call transcript
2020 Q4
5 Feb 21
REGN
Earnings call transcript
2020 Q3
5 Nov 20
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 3.12 bn | 3.12 bn | 3.12 bn | 3.12 bn | 3.12 bn | 3.12 bn |
| Cash burn (monthly) | 128.47 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 394.93 mm | n/a | n/a | n/a | n/a | n/a |
| Cash remaining | 2.72 bn | n/a | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 21.2 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2022
87.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1110 |
| Opened positions | 168 |
| Closed positions | 95 |
| Increased positions | 321 |
| Reduced positions | 441 |
| 13F shares | Current |
|---|---|
| Total value | 66.29 tn |
| Total shares | 93.62 mm |
| Total puts | 1.92 mm |
| Total calls | 1.46 mm |
| Total put/call ratio | 1.3 |
| Largest owners | Shares | Value |
|---|---|---|
| FMR | 11.10 mm | $8.01 tn |
| BLK Blackrock | 9.17 mm | $6.61 tn |
| Vanguard | 8.72 mm | $6.29 tn |
| Capital World Investors | 6.24 mm | $4.50 tn |
| JPM JPMorgan Chase & Co. | 6.11 mm | $4.41 tn |
| STT State Street | 4.96 mm | $3.58 tn |
| Wellington Management | 2.42 mm | $1.74 tn |
| Dodge & Cox | 2.22 mm | $1.60 tn |
| Geode Capital Management | 2.21 mm | $1.59 tn |
| T. Rowe Price | 1.72 mm | $1.24 tn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Mar 23 | Landry Robert E | Common Stock | Sell | Dispose S | No | Yes | 826.36 | 31 | 25.62 k | 31,922 |
| 28 Mar 23 | Landry Robert E | Common Stock | Sell | Dispose S | No | Yes | 825.37 | 243 | 200.56 k | 31,953 |
| 28 Mar 23 | Landry Robert E | Common Stock | Sell | Dispose S | No | Yes | 824.54 | 157 | 129.45 k | 32,196 |
| 28 Mar 23 | Landry Robert E | Common Stock | Sell | Dispose S | No | Yes | 823.6 | 181 | 149.07 k | 32,353 |
| 28 Mar 23 | Landry Robert E | Common Stock | Sell | Dispose S | No | Yes | 822.67 | 128 | 105.30 k | 32,534 |
| 28 Mar 23 | Landry Robert E | Common Stock | Sell | Dispose S | No | Yes | 821.4 | 142 | 116.64 k | 32,662 |
| 28 Mar 23 | Landry Robert E | Common Stock | Sell | Dispose S | No | Yes | 820.85 | 115 | 94.40 k | 32,804 |
| 28 Mar 23 | Landry Robert E | Common Stock | Sell | Dispose S | No | Yes | 818.81 | 10 | 8.19 k | 32,919 |
| 27 Mar 23 | Landry Robert E | Common Stock | Sell | Dispose S | No | Yes | 830.01 | 7 | 5.81 k | 32,929 |
| 27 Mar 23 | Landry Robert E | Common Stock | Sell | Dispose S | No | Yes | 829.16 | 4 | 3.32 k | 32,936 |
News
JP Morgan Maintains Overweight Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
31 Mar 23
NVIDIA To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday
31 Mar 23
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950
31 Mar 23
B of A Securities Maintains Underperform on Regeneron Pharmaceuticals, Raises Price Target to $650
29 Mar 23
The European Commission Has Approved Regeneron Pharmaceuticals' Libtayo (Cemiplimab) Plus Platinum-Based Chemotherapy For First-Line Treatment Of Advanced Non-Small Cell Lung Cancer With ≥1% PD-L1 Expression
29 Mar 23
Press releases
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
28 Mar 23
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
28 Mar 23
Thinking about trading options or stock in Regeneron Pharmaceuticals, NetEase, Netflix, Advanced Micro Devices, or Novo Nordisk?
23 Mar 23
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
23 Mar 23
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
23 Mar 23